Development of diaminoquinazoline histone lysine methyltransferase inhibitors as potent blood-stage antimalarial compounds

Sandeep Sundriyal, Nicholas A Malmquist, Joachim Caron, Scott Blundell, Feng Liu, Xin Chen, Nitipol Srimongkolpithak, JIan Jin, Susan Ann Charman, Artur Scherf, Matthew J Fuchter

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Modulating epigenetic mechanisms in malarial parasites is an emerging avenue for the discovery of novel antimalarial drugs. Previously we demonstrated the potent in vitro and in vivo antimalarial activity of (1-benzyl-4-piperidyl)[6,7-dimethoxy-2-(4-methyl-1,4-diazepin-1-yl)-4-quinazolinyl]amine (BIX01294; 1), a known human G9a inhibitor, together with its dose-dependent effects on histone methylation in the malarial parasite. This work describes our initial medicinal chemistry efforts to optimise the diaminoquinazoline chemotype for antimalarial activity. A variety of analogues were designed by substituting the 2 and 4 positions of the quinazoline core, and these molecules were tested against Plasmodium falciparum (3D7 strain). Several analogues with IC50 values as low as 18.5 nM and with low mammalian cell toxicity (HepG2) were identified. Certain pharmacophoric features required for antimalarial activity were found to be analogous to the previously published SAR of these analogues for G9a inhibition, thereby suggesting potential similarities between the malarial and human HKMT targets of this chemotype. Physiochemical, in vitro activity, and in vitro metabolism studies were also performed for a select set of potent analogues to evaluate their potential as antimalarial leads.
Original languageEnglish
Pages (from-to)2360 - 2373
Number of pages14
JournalChemMedChem
Volume9
Issue number10
DOIs
Publication statusPublished - 2014

Cite this

Sundriyal, S., Malmquist, N. A., Caron, J., Blundell, S., Liu, F., Chen, X., ... Fuchter, M. J. (2014). Development of diaminoquinazoline histone lysine methyltransferase inhibitors as potent blood-stage antimalarial compounds. ChemMedChem, 9(10), 2360 - 2373. https://doi.org/10.1002/cmdc.201402098
Sundriyal, Sandeep ; Malmquist, Nicholas A ; Caron, Joachim ; Blundell, Scott ; Liu, Feng ; Chen, Xin ; Srimongkolpithak, Nitipol ; Jin, JIan ; Charman, Susan Ann ; Scherf, Artur ; Fuchter, Matthew J. / Development of diaminoquinazoline histone lysine methyltransferase inhibitors as potent blood-stage antimalarial compounds. In: ChemMedChem. 2014 ; Vol. 9, No. 10. pp. 2360 - 2373.
@article{ac734f205c814fd1bb5556abdfecf7d5,
title = "Development of diaminoquinazoline histone lysine methyltransferase inhibitors as potent blood-stage antimalarial compounds",
abstract = "Modulating epigenetic mechanisms in malarial parasites is an emerging avenue for the discovery of novel antimalarial drugs. Previously we demonstrated the potent in vitro and in vivo antimalarial activity of (1-benzyl-4-piperidyl)[6,7-dimethoxy-2-(4-methyl-1,4-diazepin-1-yl)-4-quinazolinyl]amine (BIX01294; 1), a known human G9a inhibitor, together with its dose-dependent effects on histone methylation in the malarial parasite. This work describes our initial medicinal chemistry efforts to optimise the diaminoquinazoline chemotype for antimalarial activity. A variety of analogues were designed by substituting the 2 and 4 positions of the quinazoline core, and these molecules were tested against Plasmodium falciparum (3D7 strain). Several analogues with IC50 values as low as 18.5 nM and with low mammalian cell toxicity (HepG2) were identified. Certain pharmacophoric features required for antimalarial activity were found to be analogous to the previously published SAR of these analogues for G9a inhibition, thereby suggesting potential similarities between the malarial and human HKMT targets of this chemotype. Physiochemical, in vitro activity, and in vitro metabolism studies were also performed for a select set of potent analogues to evaluate their potential as antimalarial leads.",
author = "Sandeep Sundriyal and Malmquist, {Nicholas A} and Joachim Caron and Scott Blundell and Feng Liu and Xin Chen and Nitipol Srimongkolpithak and JIan Jin and Charman, {Susan Ann} and Artur Scherf and Fuchter, {Matthew J}",
year = "2014",
doi = "10.1002/cmdc.201402098",
language = "English",
volume = "9",
pages = "2360 -- 2373",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "Wiley-VCH Verlag GmbH & Co. KGaA",
number = "10",

}

Sundriyal, S, Malmquist, NA, Caron, J, Blundell, S, Liu, F, Chen, X, Srimongkolpithak, N, Jin, JI, Charman, SA, Scherf, A & Fuchter, MJ 2014, 'Development of diaminoquinazoline histone lysine methyltransferase inhibitors as potent blood-stage antimalarial compounds' ChemMedChem, vol. 9, no. 10, pp. 2360 - 2373. https://doi.org/10.1002/cmdc.201402098

Development of diaminoquinazoline histone lysine methyltransferase inhibitors as potent blood-stage antimalarial compounds. / Sundriyal, Sandeep; Malmquist, Nicholas A; Caron, Joachim; Blundell, Scott; Liu, Feng; Chen, Xin; Srimongkolpithak, Nitipol; Jin, JIan; Charman, Susan Ann; Scherf, Artur; Fuchter, Matthew J.

In: ChemMedChem, Vol. 9, No. 10, 2014, p. 2360 - 2373.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Development of diaminoquinazoline histone lysine methyltransferase inhibitors as potent blood-stage antimalarial compounds

AU - Sundriyal, Sandeep

AU - Malmquist, Nicholas A

AU - Caron, Joachim

AU - Blundell, Scott

AU - Liu, Feng

AU - Chen, Xin

AU - Srimongkolpithak, Nitipol

AU - Jin, JIan

AU - Charman, Susan Ann

AU - Scherf, Artur

AU - Fuchter, Matthew J

PY - 2014

Y1 - 2014

N2 - Modulating epigenetic mechanisms in malarial parasites is an emerging avenue for the discovery of novel antimalarial drugs. Previously we demonstrated the potent in vitro and in vivo antimalarial activity of (1-benzyl-4-piperidyl)[6,7-dimethoxy-2-(4-methyl-1,4-diazepin-1-yl)-4-quinazolinyl]amine (BIX01294; 1), a known human G9a inhibitor, together with its dose-dependent effects on histone methylation in the malarial parasite. This work describes our initial medicinal chemistry efforts to optimise the diaminoquinazoline chemotype for antimalarial activity. A variety of analogues were designed by substituting the 2 and 4 positions of the quinazoline core, and these molecules were tested against Plasmodium falciparum (3D7 strain). Several analogues with IC50 values as low as 18.5 nM and with low mammalian cell toxicity (HepG2) were identified. Certain pharmacophoric features required for antimalarial activity were found to be analogous to the previously published SAR of these analogues for G9a inhibition, thereby suggesting potential similarities between the malarial and human HKMT targets of this chemotype. Physiochemical, in vitro activity, and in vitro metabolism studies were also performed for a select set of potent analogues to evaluate their potential as antimalarial leads.

AB - Modulating epigenetic mechanisms in malarial parasites is an emerging avenue for the discovery of novel antimalarial drugs. Previously we demonstrated the potent in vitro and in vivo antimalarial activity of (1-benzyl-4-piperidyl)[6,7-dimethoxy-2-(4-methyl-1,4-diazepin-1-yl)-4-quinazolinyl]amine (BIX01294; 1), a known human G9a inhibitor, together with its dose-dependent effects on histone methylation in the malarial parasite. This work describes our initial medicinal chemistry efforts to optimise the diaminoquinazoline chemotype for antimalarial activity. A variety of analogues were designed by substituting the 2 and 4 positions of the quinazoline core, and these molecules were tested against Plasmodium falciparum (3D7 strain). Several analogues with IC50 values as low as 18.5 nM and with low mammalian cell toxicity (HepG2) were identified. Certain pharmacophoric features required for antimalarial activity were found to be analogous to the previously published SAR of these analogues for G9a inhibition, thereby suggesting potential similarities between the malarial and human HKMT targets of this chemotype. Physiochemical, in vitro activity, and in vitro metabolism studies were also performed for a select set of potent analogues to evaluate their potential as antimalarial leads.

UR - http://onlinelibrary.wiley.com/doi/10.1002/cmdc.201402098/epdf

U2 - 10.1002/cmdc.201402098

DO - 10.1002/cmdc.201402098

M3 - Article

VL - 9

SP - 2360

EP - 2373

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 10

ER -